🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: LMT (atorvastatin, simvastatin, or rosuvastatin)

Found 12 matching trials

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)

PHASE3

Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that bi...

Status

Completed

Location

Investigational Site Number 840857

Start Date

2012-07

Trial ID

NCT01644175

Treatments Being Tested

Placebo (for alirocumab)Alirocumab Lipid-Modifying Therapy (LMT)

Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)

PHASE3

Primary Objective: To provide participants with severe hypercholesterolemi...

Status

Completed

Location

Investigational Site Number 040001

Start Date

2015-06-23

Trial ID

NCT02476006

Treatments Being Tested

ALIROCUMAB SAR236553 (REGN727)placebo (for injection training only)ezetimibe atorvastatin rosuvastatin simvastatin

Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan

PHASE3

Primary Objective: To demonstrate the reduction of low-density lipoprotein...

Status

Completed

Location

Investigational Site Number 410001

Start Date

2015-01

Trial ID

NCT02289963

Treatments Being Tested

Placebo (for Alirocumab)Alirocumab Lipid-Modifying Therapy (LMT)

Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

PHASE3

Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that bi...

Status

Completed

Location

Investigational Site Number 840159

Start Date

2012-01

Trial ID

NCT01507831

Treatments Being Tested

Placebo (for alirocumab)Alirocumab Lipid-Modifying Therapy (LMT)

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

PHASE3

Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that bi...

Status

Completed

Location

Investigational Site Number 840417

Start Date

2012-07

Trial ID

NCT01623115

Treatments Being Tested

Alirocumab Placebo (for alirocumab)Lipid Modifying Therapy (LMT)

Open Label Study of Long Term Safety Evaluation of Alirocumab

PHASE3

Primary Objective: To assess the long-term safety of alirocumab (SAR236553...

Status

Completed

Location

Investigational Site Number 840321

Start Date

2013-12-17

Trial ID

NCT01954394

Treatments Being Tested

Alirocumab Lipid-Modifying Therapy (LMT)

Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)

PHASE3

This is a randomized, double-blind, placebo-controlled, parallel-group, mul...

Status

Completed

Location

Multiple Locations

Start Date

2012-12

Trial ID

NCT01709500

Treatments Being Tested

LMT (atorvastatin, simvastatin, or rosuvastatin)alirocumab Placebo

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)

PHASE3

Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that bi...

Status

Completed

Location

Investigational Site Number 840742

Start Date

2012-06

Trial ID

NCT01617655

Treatments Being Tested

Alirocumab Placebo (for alirocumab)Lipid Modifying Therapy (LMT)

Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)

PHASE3

Primary Objective: To demonstrate the reduction of low-density lipoprotein...

Status

Completed

Location

Investigational Site Number 392016

Start Date

2014-03

Trial ID

NCT02107898

Treatments Being Tested

Placebo (for alirocumab)Alirocumab Lipid-Modifying Therapy (LMT)

Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia

PHASE3

Primary Objective: To demonstrate the reduction of low-density lipoprotein...

Status

Completed

Location

Investigational Site Number 1560027

Start Date

2016-07-27

Trial ID

NCT02715726

Treatments Being Tested

Alirocumab Placebo for alirocumab ezetimibe placebo for ezetimibe atorvastatin rosuvastatin simvastatin

Previous Next